Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/7375
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fitria, Najmiatul | - |
dc.contributor.author | Syaputri, Yolanda Zazna | - |
dc.contributor.author | Akram, Muhammad | - |
dc.contributor.author | Nasif, Hansen | - |
dc.contributor.author | Mardatillah | - |
dc.date.accessioned | 2024-11-06T08:21:41Z | - |
dc.date.available | 2024-11-06T08:21:41Z | - |
dc.date.issued | 2024-04 | - |
dc.identifier.citation | Original Article | en_US |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/7375 | - |
dc.description.abstract | Introduction: The combination of amlodipine and candesartan can have a better effect, although the costeffectiveness analysis was not yet determined. This research aimed to establish the Incremental Cost-Effectiveness Ratio (ICER) value among outpatients with hypertension who used amlodipine-candesartan. Method: This research was a descriptive study that retrospectively gathered data from medical records . Medical records data focused on information for hypertensive patients at Universitas Andalas Hospital in 2021. This study compared the standard treatment involving amlodipine-candesartan and sole amlodipine, next to calculate the ICER using cost-effectiveness analysis. Results: Out of the total population of 284, as many as 73 patients were involved in this study. Among these, 21 patients (28.77%) were treated with amlodipine alone, while 52 (71.23%) received an amlodipine-candesartan combination. The Incremental Cost-Effectiveness Ratio (ICER) for reducing systolic blood pressure was IDR 74,738.10 per one mmHg decrease in the northeast quadrant of the cost-effectiveness chart. The ICER for lowering diastolic blood pressure was IDR 205,918.24 per one mmHg decrease in the northeast quadrant on the cost-effectiveness chart. Conclusion: The cost of the amlodipine-candesartan combination yields superior effects; however, warranting a probabilistic sensitivity analysis to determine its ICER robustness is essential for its effective implementation. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Jurnal Sains Farmasi & Klinis | en_US |
dc.subject | amlodipine | en_US |
dc.subject | antihypertension | en_US |
dc.subject | candesartan | en_US |
dc.subject | cost-effectiveness analysis | en_US |
dc.subject | incremental cost-effectiveness ratio | en_US |
dc.title | Amlodipine-Candesartan Combination: A Cost-Effective Strategy for Successful Therapy of Hypertension | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 11 NO 1 2024 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.